Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: An overview

Acta Neurologica Belgica

Volumn 113, Issue 4, 2013, Pages 381-390

  Javaid, Mohammad A ^a   Abdallah, Mohamed Nur ^a   Ahmed, Ahad S ^b   Sheikh, Zeeshan ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ALTAMASH INSTITUTE OF DENTAL MEDICINE   (Pakistan)

Author keywords

Experimental autoimmune encephalomyelitis; Extracellular matrix; Matrix metalloproteinases; Multiple sclerosis

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERFERON BETA SERINE; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 26; MINOCYCLINE; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3;

ASTROCYTE; BLOOD BRAIN BARRIER; CELL INFILTRATION; DEMYELINATION; DISABILITY; ENZYME ACTIVATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLIOSIS; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; TISSUE INJURY; UPREGULATION;

ANIMALS; HUMANS; MATRIX METALLOPROTEINASES; MULTIPLE SCLEROSIS; UP-REGULATION;

EID: 84891656767     PISSN: 03009009     EISSN: 22402993     Source Type: Journal    
DOI: 10.1007/s13760-013-0239-x     Document Type: Review

References (70)

1. Yong VW et al (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2(7): 502-511.
2. Yong VW (1999) The potential use of MMP inhibitors to treat CNS diseases. Expert Opin Investig Drugs 8(3): 255-268.
3. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16(5): 558-564.
4. Yong VW (2005) Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6(12): 931-944.
5. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8(2): 205-216.
6. Brinckerhoff CE, Matrisian LM (2002) Timeline-matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3(3): 207-214.
7. Verma RP, Hansch C (2007) Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem 15(6): 2223-2268.
8. Belvisi M, Bottomley K (2003) The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res 52(3): 95-100.
9. Georgiadis D, Yiotakis A (2008) Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem 16(19): 8781-8794.
10. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516.
11. Vincenti MP, Brinckerhoff CE (2007) Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J Cell Physiol 213(2): 355-364.
12. Cunningham LA, Wetzel M, Rosenberg GA (2005) Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50(4): 329-339.
13. Makowski GS, Ramsey ML (1998) Binding of matrix metalloproteinase 9 to fibrin is mediated by amorphous calcium-phosphate. Inflammation 22(6): 599-617.
14. Okada Y et al (1990) Matrix metalloproteinase-2 from human rheumatoid synovial fibroblasts: purification and activation of the precursor and enzymatic-properties. Eur J Biochem 194(3): 721-730.
15. Bernal F et al (2009) Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult Scler 15(6): 721-727.
16. Kieseier BC et al (1998) Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121(Pt 1): 159-166.
17. Agrawal SM, Lau L, Yong VW (2008) MMPs in the central nervous system: where the good guys go bad. Semin Cell Develop Biol 19: 42-51.
18. Newman TA et al (2001) T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 124(Pt 11): 2203-2214.
19. Agrawal SM, Yong VW (2007) Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol 79: 99-126.
20. Brundula V et al (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125(Pt 6): 1297-1308.
21. Alexander JS et al (2010) Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 16(7): 801-809.
22. Chandler S et al (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72(2): 155-161.
23. Benešová Y et al (2009) Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Multiple Scler 15(3): 316-322.
24. Leppert D et al (1998) Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121(Pt 12): 2327-2334.
25. Chandler S et al (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72(2): 155-161.
26. Gasche Y et al (2006) Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front Biosci 11: 1289-1301.
27. Lichtinghagen R et al (1999) Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 99(1): 19-26.
28. Anthony DC et al (1997) Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23(5): 406-415.
29. Toft-Hansen H et al (2004) Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol 173(8): 5209-5218.
30. Teesalu T, Hinkkanen AE, Vaheri A (2001) Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am J Pathol 159(6): 2227-2237.
31. Graesser D et al (1998) The interrelationship of alpha4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis. Lab Invest 78(11): 1445-1458.
32. Nygardas PT, Hinkkanen AE (2002) Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin Exp Immunol 128(2): 245-254.
33. Clements JM et al (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74(1-2): 85-94.
34. Dasilva AG, Yong VW (2008) Expression and regulation of matrix metalloproteinase-12 in experimental autoimmune encephalomyelitis and by bone marrow derived macrophages in vitro. J Neuroimmunol 199(1-2): 24-34.
35. Goncalves DaSilva A, Liaw L, Yong VW (2010) Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice. Am J Pathol 177(3): 1448-1458.
36. Rosenberg GA (2002) Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8(6): 586-595.
37. Rosenberg GA et al (1992) TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576(2): 203-207.
38. Rosenberg GA et al (1994) Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab Invest 71(3): 417-422.
39. Rosenberg GA et al (1995) Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 703(1-2): 151-155.
40. Shiryaev SA et al (2009) Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One 4(3): e4952.
41. Latronico T et al (2013) Inhibition of myelin-cleaving poteolytic activities by interferon-beta in rat astrocyte cultures. Comparative analysis between gelatinases and calpain-II. PLoS One 8(2): e49656.
42. Niimi N, Kohyama K, Matsumoto Y (2013) Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases. Neuropathology.
43. Marracci GH et al (2002) Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 131(1-2): 104-114.
44. Dubois B et al (1999) Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104(11): 1507-1515.
45. Yong VW et al (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immuno modulators. J Neurol Sci 259(1-2): 79-84.
46. Folgueras AR et al (2008) Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J Biol Chem 283(14): 9465-9474.
47. Shipley JM et al (1996) Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 93(9): 3942-3946.
48. Gijbels K et al (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41(1): 29-34.
49. Cuzner ML, Opdenakker G (1999) Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 94(1-2): 1-14.
50. Lee MA et al (1999) Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122(Pt 2): 191-197.
51. Fernandes KS et al (2009) Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol 214(1-2): 128-131.
52. Benesova Y et al (2012) An Association between matrix metalloproteinase-2 and TIMP-2 + 853G/A gene polymorphisms and multiple sclerosis. Česká a slovenská neurologie a neurochirurgie 75(3): 314-319.
53. Benesova Y et al (2008) Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J Neuroimmunol 205(1-2): 105-109.
54. Liuzzi GM et al (2002) Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 8(3): 222-228.
55. Lindberg RL et al (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124(Pt 9): 1743-1753.
56. Cossins JA et al (1997) Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 94(6): 590-598.
57. Maeda A, Sobel RA (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55(3): 300-309.
58. Cuzner ML et al (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55(12): 1194-1204.
59. Bar-Or A et al (2003) Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 126(12): 2738-2749.
60. Apodaca G et al (1990) Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50(8): 2322-2329.
61. Uhm JH et al (1999) Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann Neurol 46(3): 319-324.
62. Deb S, Gottschall PE (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66(4): 1641-1647.
63. Yong VW et al (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21(2): 75-80.
64. Gray E et al (2008) Elevated matrix metalloproteinase-9 and degradation of perineuronal nets in cerebrocortical multiple sclerosis plaques. J Neuropathol Exp Neurol 67(9): 888-899.
65. Ozenci V et al (2000) Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 108(1-2): 236-243.
66. Stuve O et al (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40(6): 853-863.
67. Leppert D et al (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40(6): 846-852.
68. Trojano M et al (1999) Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53(7): 1402-1408.
69. Moss ML et al (2001) TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today 6(8): 417-426.
70. Larsen PH et al (2003) Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 23(35): 11127-11135.